MA34909B1 - Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih - Google Patents

Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih

Info

Publication number
MA34909B1
MA34909B1 MA36183A MA36183A MA34909B1 MA 34909 B1 MA34909 B1 MA 34909B1 MA 36183 A MA36183 A MA 36183A MA 36183 A MA36183 A MA 36183A MA 34909 B1 MA34909 B1 MA 34909B1
Authority
MA
Morocco
Prior art keywords
triterpenoids
modified
inhibitory activity
hiv maturation
compounds
Prior art date
Application number
MA36183A
Other languages
English (en)
Inventor
Alicia Regueiro-Ren
Zheng Liu
Jacob Swidorski
Brian Lee Sin Ny Venables
Sing-Yuen Sit
Yan Chen
Nicholas A Meanwell
Jie Chen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA34909B1 publication Critical patent/MA34909B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS AYANT DES PROPRIÉTÉS MÉDICAMENTEUSES ET BIOLOGIQUES, LEURS COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION. EN PARTICULIER, L'INVENTION CONCERNE DES TRITERPÉNOÏDES MODIFIÉS EN C-17 ET EN C-3 QUI POSSÈDENT UNE ACTIVITÉ ANTIVIRALE UNIQUE, EN TANT QU'INHIBITEURS DE MATURATION DU VIH, TEL QUE REPRÉSENTÉ PAR DES COMPOSÉS DES FORMULES I, II ET III. CES COMPOSÉS SONT UTILES POUR LE TRAITEMENT DU VIH ET DU SIDA.
MA36183A 2011-01-31 2012-01-27 Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih MA34909B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437893P 2011-01-31 2011-01-31
PCT/US2012/022852 WO2012106190A1 (fr) 2011-01-31 2012-01-27 Triterpénoïdes modifiés en c-17 et c-3 présentant une activité inhibitrice de la maturation du vih

Publications (1)

Publication Number Publication Date
MA34909B1 true MA34909B1 (fr) 2014-02-01

Family

ID=45567147

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36183A MA34909B1 (fr) 2011-01-31 2012-01-27 Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih

Country Status (25)

Country Link
US (3) US8846647B2 (fr)
EP (1) EP2670765B1 (fr)
JP (1) JP6001560B2 (fr)
KR (1) KR101886467B1 (fr)
CN (1) CN103429607B (fr)
AR (1) AR085053A1 (fr)
AU (1) AU2012212509B2 (fr)
BR (1) BR112013019419A2 (fr)
CA (1) CA2826113C (fr)
CL (1) CL2013002185A1 (fr)
CO (1) CO6751275A2 (fr)
EA (1) EA022470B1 (fr)
ES (1) ES2653847T3 (fr)
IL (1) IL227678B (fr)
MA (1) MA34909B1 (fr)
MY (1) MY162186A (fr)
PE (1) PE20141152A1 (fr)
PH (1) PH12013501528A1 (fr)
PT (1) PT2670765T (fr)
SG (1) SG192144A1 (fr)
TN (1) TN2013000321A1 (fr)
TW (1) TWI628188B (fr)
UY (1) UY33886A (fr)
WO (1) WO2012106190A1 (fr)
ZA (1) ZA201306546B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022588B1 (ru) 2008-04-18 2016-01-29 Ритэ Фамэсутикл, Инк. Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце
MX2010011435A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
WO2009129548A1 (fr) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Modulateurs d’inflammation antioxydants : dérivés d’acide oléanolique homologués c-17
DK2276493T3 (da) 2008-04-18 2019-01-02 Reata Pharmaceuticals Inc Antioxidative inflammationsmodulatorer: oleanolsyrederivater med amino- og andre modifikationer ved c-17
NZ612788A (en) 2010-12-17 2015-10-30 Reata Pharmaceuticals Inc Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
SI2670764T1 (sl) * 2011-01-31 2016-03-31 Bristol-Myers Squibb Company C-28 amini derivatov c-3 modificirane betulinske kisline inhibitorjev zorenja hiv
EP2683731B1 (fr) 2011-03-11 2019-04-24 Reata Pharmaceuticals, Inc. Dérivés monométhyle triterpénoïdes en c4 et leurs procédés d'utilisation
MX2014002936A (es) 2011-09-21 2014-04-25 Bristol Myers Squibb Co Nuevos derivados de acido betulinico con actividad antiviral.
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
SI3444261T1 (sl) 2012-04-27 2021-04-30 Reata Pharmaceuticals, Inc. 2,2-difluoropropionamidni derivat bardoksolon metila, njegovi farmacevtski sestavki in polimorfi za uporabo pri zdravljenju določenih stanj
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
WO2013188818A1 (fr) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. Modulateurs anti-inflammation basés sur des triterpénoïdes époxydés au niveau du cycle a et leurs méthodes d'utilisation
ES2893473T3 (es) * 2012-08-15 2022-02-09 Glaxo Group Ltd Proceso químico
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
PL2892912T3 (pl) 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US20140221361A1 (en) * 2013-02-06 2014-08-07 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity
CN105102468A (zh) * 2013-02-25 2015-11-25 百时美施贵宝公司 用于治疗hiv的c-3烷基和烯基修饰的桦木酸衍生物
PL3129392T3 (pl) 2014-04-11 2021-04-06 VIIV Healthcare UK(No.4) Limited Triterpenoidy o aktywności hamującej dojrzewanie hiv, podstawione w pozycji 3 niearomatycznym pierścieniem zawierającym podstawnik fluorowcoalkilowy
WO2015195776A1 (fr) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Dérivés d'acide bétulinique présentant une activité inhibitrice de maturation du vih
BR112017009850A2 (pt) 2014-11-14 2018-01-16 Viiv Healthcare Uk No 5 Ltd composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
KR20170092581A (ko) * 2014-11-14 2017-08-11 비브 헬스케어 유케이 (넘버5) 리미티드 Ｃ１７-아릴 치환된 베툴린산 유사체
WO2016168447A1 (fr) 2015-04-14 2016-10-20 VIIV HEALTHCARE (No.4) LIMITED Méthodes de production d'un inhibiteur de la maturation du vih
EP3328876A1 (fr) 2015-07-28 2018-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Dérivés de bétuine permettant de ou de traiter des infections à vih
KR20180028535A (ko) 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
WO2017025901A1 (fr) * 2015-08-11 2017-02-16 Hetero Research Foundation Nouveaux analogues de c28 à modifications en c3 de dérivés triterpéniques à utiliser en tant qu'inhibiteurs du vih
MX386256B (es) 2015-09-23 2025-03-18 Reata Pharmaceuticals Inc Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
AU2016327169A1 (en) 2015-09-24 2018-04-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
AU2016356335A1 (en) 2015-11-20 2018-05-31 ViiV Healthcare UK (No.4) Limited HIV maturation inhibitor formulations
JP2019502728A (ja) 2016-01-20 2019-01-31 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｈｉｖ成熟阻害活性を有するルパンのアミン誘導体
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
US20190135857A1 (en) * 2016-06-30 2019-05-09 Viiv Healthcare Uk (No. 5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
WO2018044822A1 (fr) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinaisons, utilisations et traitements correspondants
CN118440135A (zh) 2017-08-04 2024-08-06 阿德利克斯股份有限公司 用于治疗高钾血症的甘草次酸衍生物
JP6977474B2 (ja) * 2017-10-23 2021-12-08 東京エレクトロン株式会社 半導体装置の製造方法
JP6926939B2 (ja) * 2017-10-23 2021-08-25 東京エレクトロン株式会社 半導体装置の製造方法
EP3784349B1 (fr) 2018-04-24 2023-12-27 VIIV Healthcare UK (No.5) Limited Composés ayant une activité inhibitrice de la maturation du vih
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
TWI861053B (zh) 2019-02-07 2024-11-11 美商阿德利克斯公司 用於治療高鉀血症之化合物及方法
US12275712B2 (en) 2019-02-11 2025-04-15 Hetero Labs Limited Triterpene derivatives as HIV inhibitors
WO2021016191A1 (fr) 2019-07-19 2021-01-28 Reata Pharmaceuticals, Inc. Triterpénoïdes synthétiques hétéroaromatiques à substitution polaire c17 et leurs procédés d'utilisation
GB2598300A (en) * 2020-08-21 2022-03-02 Univ Durham Cross-linking method and applications in bioconjugation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
WO2004089357A2 (fr) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Preparation antifongique a base de triterpene et d'huile essentielle
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
AU2005224260A1 (en) 2004-03-17 2005-09-29 Panacos Pharmaceuticals, Inc. Pharmaceuticals salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US8067620B2 (en) 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
WO2008127364A2 (fr) * 2006-10-13 2008-10-23 Myriad Genetics, Inc. Composés antiviraux et utilisation de ceux-ci
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
AU2009214779A1 (en) * 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17beta lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
ES2548905T3 (es) * 2010-06-04 2015-10-21 Bristol-Myers Squibb Company Amidas C-28 de derivados del ácido betulínico C-3 modificados como inhibidores de la maduración del VIH
EP2576585B8 (fr) * 2010-06-04 2016-12-21 VIIV Healthcare UK (No.5) Limited Dérivés d'acide bétulinique modifiés en c-3, utilisés comme inhibiteurs de maturation du vih

Also Published As

Publication number Publication date
TW201309717A (zh) 2013-03-01
US8846647B2 (en) 2014-09-30
CO6751275A2 (es) 2013-09-16
KR101886467B1 (ko) 2018-08-07
JP6001560B2 (ja) 2016-10-05
PT2670765T (pt) 2018-01-08
US20140343000A1 (en) 2014-11-20
BR112013019419A2 (pt) 2019-12-03
ES2653847T3 (es) 2018-02-09
US20130035318A1 (en) 2013-02-07
EA201391127A1 (ru) 2013-12-30
IL227678B (en) 2018-04-30
CN103429607B (zh) 2016-02-17
JP2014503595A (ja) 2014-02-13
AU2012212509A1 (en) 2013-09-19
AR085053A1 (es) 2013-08-07
EP2670765A1 (fr) 2013-12-11
KR20140016279A (ko) 2014-02-07
EP2670765B1 (fr) 2017-10-18
EA022470B1 (ru) 2016-01-29
NZ614871A (en) 2014-06-27
US20160151387A1 (en) 2016-06-02
WO2012106190A1 (fr) 2012-08-09
ZA201306546B (en) 2015-03-25
PE20141152A1 (es) 2014-09-22
PH12013501528A1 (en) 2013-09-16
CN103429607A (zh) 2013-12-04
CL2013002185A1 (es) 2013-12-27
IL227678A0 (en) 2013-09-30
CA2826113C (fr) 2018-09-04
MY162186A (en) 2017-05-31
UY33886A (es) 2012-07-31
SG192144A1 (en) 2013-08-30
AU2012212509B2 (en) 2016-01-21
TWI628188B (zh) 2018-07-01
CA2826113A1 (fr) 2012-08-09
TN2013000321A1 (en) 2015-01-20

Similar Documents

Publication Publication Date Title
MA34909B1 (fr) Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih
MX2022009942A (es) Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
EP2493464A4 (fr) Méthylsulfonylméthane (msm) pour le traitement de micro-organismes résistants aux médicaments
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA41013A (fr) Compositions comprenant des souches bactériennes
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA43960B1 (fr) Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1
MA41185B1 (fr) Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc
EA201491531A1 (ru) C-3 циклоалкенил тритерпеноиды, ингибирующие созревание вич
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
MA35638B1 (fr) 2-thiopyrimidinones
MA39170B1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
MA40886B1 (fr) Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
EP2555798A4 (fr) Procédés et compositions pour l'inhibition de la transmission du vih
MA39374A1 (fr) Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA38678A1 (fr) Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
MA35281B1 (fr) Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques
MA38009B1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer
EP2491143A4 (fr) Méthodes et compositions utilisées pour le diagnostic et le traitement d'une rétinopathie génétique
EP2931040A4 (fr) Méthodes et compositions pour le traitement d'une infection par le vih